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Abstract: Clindamycin has been used successfully to treat pneumonia and soft-tissue infections caused by methicillin-
resistant Staphylococcus aureus. However, inducible clindamycin resistance has been described as a cause of treatment 
failure of such infections. A total of 159 staphylococcal isolates from different clinical specimens from burn patients in 
Tripoli Burn Center were tested for inducible clindamycin resistance by the disk-diffusion induction test. Inducible 
clindamycin resistance was detected in 66.2% of 65 methicillin-resistant S. aureus isolates and in none of 55 methicillin-
sensitive S. aureus, 10 methicillin-resistant coagulase negative staphylococci and 29 methicllin-sensitive coagulase negative 
staphylococci isolates. In our setting, clindamycin can be used for the treatment of infections due to staphylococci, but we 
recommend that staphylococci isolates, particularly methicillin-resistant S. aureus, are tested by the D-test before 
treatment. 
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Introduction 
Burn patients are extremely susceptible to infections 
caused by Gram-positive organisms, particularly 
staphylococci [1]. Staphylococcus aureus has been 
recognized as one of the major causes of nosocomial 
infections worldwide, and its resistance to antimicrobials 
has complicated the treatment of infections due to these 
microorganisms. Clindamycin is frequently used to treat 
some staphylococcal infections, particularly skin and soft-
tissue infections, and as an alternative in penicillin-allergic 
patients [2]. In addition, clindamycin has been shown to 
inhibit the production of S. aureus toxins, including 
Panton-Valentine Leukocidin toxin [3]. 
 
One of the major concerns regarding the use of 
clindamycin to treat staphylococcal infections is the 
possible presence of inducible resistance to clindamycin 
(ICR) [4,5]. In S. aureus and coagulase-negative 
staphylococci (CoNS), resistance to macrolides (e.g. 
erythromycin), lincosamides (e.g. clindmycin) and type B 
streptogramins (MLSB) can be the result of ribosomal 
target modification in which enzymes encoded by erm 
genes confer constitutive or inducible resistance to MLS 
drugs through methylation of the 23S rRNA [6]. Also, 
staphylococci can have an active efflux mechanism 
(encoded by msrA genes) that confers resistance to MSB 
only, but not to lincosamides [7,8]. Strains with 
constitutive resistance can be detected readily by standard 
susceptibility testing methods [9]. When tested by 
standard methods, clindamycin may appear active against 
staphylococci with IRC, and so this mode of resistance is 
identified by the disk-diffusion induction test (D-test) 
[6,7,10]. 
 
Frequencies of the different resistance patterns vary by 
geographic location, patient age, bacterial species, and 
bacterial susceptibility profile [11-17]. Because the 
incidence of ICR varies between hospitals [18], it is 
important to determine the prevalence of ICR in individual 
settings [9]. There are no data on the prevalence of ICR 
among staphylococci from clinical sources in North African 
countries, including Libya. The aim of the present work 
was to determine the prevalence of ICR among 
staphylococci isolated from infected sites of burn patients 
in Tripoli Burn Center. 
 
Materials and methods 
We examined 159 clinically significant, non-duplicate 
staphylococci isolated from different body sites of burn 
patients between January and December 2007, at the 
Burn and Plastic Surgery Centre, Tripoli, Libya. Most 
(90%) were from swabs taken from skin burn wounds, 
3% were from urine, 2% from blood, and 5% from other 
specimens. There were 65 MRSA, 55 methicillin-sensitive 
S. aureus (MSSA), 10 methicillin-resistant coagulase 
negative staphylococci (MRCoNS), and 29 methicllin-
sensitive CoNS (MSCoNS). S. aureus and CoNS were 
identified by using standard bacteriological techniques 
[19]. Methicillin resistance was detected employing the 
cefoxitin disc diffusion test (Center for Disease Control and 
Prevention [www.cdc.gov/ncidod/dhqp/ar_lab_mrsa.html]) 
and confirmed by PBP2a agglutination test. The isolates 
were tested for susceptibility to clindamycin (2 µg) and 
erythromycin (15 µg) according to CLSI criteria [20]. 
Quality control was performed with S. aureus strain ATCC 
25923 (American Type Culture Collection, Manassas, VA, 
USA). Isolates that were erythromycin-resistant (ER-R) 
and clindamycin-sensitive (CL-S) were tested for inducible 
resistance by the D-test. Erythromycin and clindamycin 
discs were placed 15 mm apart (edge to edge) on Mueller 
Hinton agar plate. Following incubation at 35°C for 17 
hours, D-test positivity (ICR) was identified by flattening 
of the clindamycin zone between the erythromycin and 
clindamycin discs. The D-test was considered negative in 
the absence of flattening of the clindamycin zone. If the 
isolate was ER-R and CL-R, the isolate was considered to 
have a constitutive MLSB (MLSBc) phenotype [2,18,21]. 
Unless stated otherwise, all materials used in the present 
work were obtained from Oxoid, Basingstoke, UK. 
 
Result 
Of the 159 staphylococci tested, 154 (96.9%) and 87 
(54.7%) were susceptible to clindamycin and 
erythromycin, respectively. Susceptibility to both drugs 
was found in 87 (54.7%) of staphylococci examined 
(Table 1). On the other hand, resistance to both 
clindamycin and erythromycin (ER-R CL-R phenotype), 
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which indicates MLSBc, was detected in only five isolates 
(3.2%); four were MRSA and one methicillin-resistant CNS 
(MRCNS). ICR was detected in 66.2% of the 65 MRSA 
isolates and in none of 55 MSSA, 10 MRCoNS and 29 
MSCoNS isolates. Susceptibility to erythromycin and 
clindamycin among the 159 staphylococci isolates 
examined is shown in Table 1. 
 
Table 1 Susceptibility to clindamycin and erythromycin among 
staphylococci isolated from burn patients. 
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MRSA 
(n=65) 
4 (6.2) 
13 
(20) 
43 
(66.2) 
5 (7.7) 
 
MSSA 
(n=55) 
0 (0.0) 
50 
(90.9) 
0 (0.0)  5 (9.1) 
MRCNS 
(n=10 ) 
1 
(10.0) 
8 
(80.0) 
0 (0.0)  1 (10.0) 
MSCNS 
(n=29 ) 
0 (0.0) 
16 
(55.1) 
0 (0.0) 
13 
(44.8) 
Staphylococci 
(n=159) 
5 (3.2) 
87 
(54.7) 
43 
(27.0) 
24 
(15.1) 
*MRSA = methicillin-resistant S. aureus, MSSA = methicillin-susceptible S. 
aureus, MRCNS = methicillin-resistant coagulase negative staphylococci, 
MSCNS = methicillin-susceptible CNS. 
**ER = erythromycin, CL = clindamycin, R = resistant, S = susceptible. 
 
Discussion 
We examined 159 staphylococci isolates from burn 
patients for their susceptibility to clindamycin and 
erythromycin. The isolates were also tested for inducible 
and constitutive clindamycin resistance. More than 96% 
(154/159) and more than 54% (87/159) of isolates were 
susceptible to clindamycin and erythromycin, respectively. 
Azap et al. [9] from Turkey examined 408 staphylococci 
isolates from different clinical sources for susceptibility to 
clindamycin and erythromycin. They reported that 68% of 
their isolates were susceptible to clindamycin and 48.5% 
for erythromycin. They also found that 32% of the isolates 
were resistant to both clindamycin and erythromycin 
(MLSBc phenotype); these were mainly MRSA and MRCNS 
isolates. Similar to their findings, we found resistance to 
both drugs only among MRSA and MRCoNS. However, the 
prevalence of resistance to both clindamycin and 
erythromycin among our staphylococci isolates was much 
lower (3%) than that reported by Azap et al [9]. 
Clindamycin is not frequently used at TBC for treatment of 
burn patients and this may explain the very high 
susceptibility rate (>96%) of staphylococci examined in 
the present study to this drug. 
 
Recently, Farrell et al [22] examined 750 clinically 
significant S. aureus from five European countries. They 
reported ICR in 38% of community-acquired MRSA (CA-
MRSA), in 6.7% of healthcare-associated MRSA (HA-
MRSA), and in 63.6% of MSSA. A study from Saudi Arabia 
tested 291 clinical isolates of ER-R CL-S staphylococci 
[23]. It reported ICR in 43% of 81 MRSA, 70% of 70 
MSSA, and 20.7% of 140 CNS. The study also found 
constitutive resistance (MLSBc) in 53%, 2.9% and 26% of 
MRSA, MSSA and CNS isolates, respectively. Here, we 
found MLSBc in 6.2% (4/65) of MRSA, 10% (1/10) of 
MRCoNS, and none of MSSA and MSCoNS. The difference 
between the prevalence of inducible and constitutive 
clindamycin resistance among our staphylococcal clinical 
isolates and those reported from the above-mentioned 
studies might be due to the type of patients studied in 
addition to the type of clinical specimens examined and 
differences in geographical location. Our staphylococci 
isolates were obtained from burn patients whereas the 
previously cited investigations were obtained from patients 
attending non-specialized general hospitals [22,23]. 
 
Failure of therapy with clindamycin in serious infections 
due to staphylococci with inducible MLSB resistance is not 
uncommon. This led to questioning the safety of using 
clindamycin for any erythromycin-resistant staphylococci 
[2,10,24,25]. We detected ICR in 27% of staphylococci 
examined and found only in MRSA. Given that most burn 
infections are in the skin and soft-tissues, clindamycin is 
an attractive treatment for such infections because of its 
tolerability, low cost, oral adminsitration, and good tissue 
penetration [2,25]. Due to the restricted range of 
antibiotics available in Libya for the treatment of 
staphylococci infections, including MRSA, and the known 
limitation of vancomycin, clindamycin should be 
considered for the management of serious soft tissue 
infections in burn patients. However, to report clindamycin 
susceptibility accurately, staphylococci isolated from 
clinical specimens should first be subjected to the D-test 
to exclude isolates with ICR. Our findings indicate that 
erythromycin resistance is often caused by active efflux in 
Libya, especially in methicillin-susceptible isolates, which 
means that clindamycin can be used in these situations 
and ICR testing can be used to confirm susceptibility. 
 
The D-test is simple, easy to perform and requires 
minimal resources. Therefore, we recommend that 
whenever clindamycin is intended for treatment of 
infections caused by staphylococci, particularly by MRSA, 
the isolated organism should be tested for ICR by the D-
test before reporting clindamycin susceptibility. We hope 
that this policy will be adopted by the health authorities in 
Libyan hospitals and clinics. In the future, more studies 
from other hospitals are required to obtain a clearer 
picture of the prevalence of ICR among staphylococci in 
North Africa.  
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